On the other hand, this supports the hypothesis that therapeutic interference with IL-17-related signaling may serve as an effective adjuvant therapy, especially in the case of LEN-based treatment regimens, enhancing its cytotoxic effects on MM cells. The gene discussed is IL17A; the disease is Miyoshi myopathy.